Evidence map›Paper›PMID 29410046›Full record

Trial reportThe Journal of allergy and clinical immunology2018

Systems biology and in vitro validation identifies family with sequence similarity 129 member A (FAM129A) as an asthma steroid response modulator.

Michael J McGeachie, George L Clemmer, Boris Hayete, Heming Xing, Karl Runge, Ann Chen Wu, Xiaofeng Jiang, Quan Lu, Bruce Church, Iya Khalil and 2 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Circulating MicroRNAs and Treatment Response in Childhood Asthma.American journal of respiratory and critical care medicine · 2020
    Trial
  2. Review
  3. Review
  4. Article
  5. Heterogeneity of Treatment Response to Asthma.Advances in experimental medicine and biology · 2023
    Article
  6. A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  7. Precision Medicine in Childhood Asthma: Omic Studies of Treatment Response.International journal of molecular sciences · 2020
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Michael J McGeachieChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass. Electronic address: michael.mcgeachie@channing.harvard.edu.
George L ClemmerChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass.
Boris HayeteGNS Healthcare, Cambridge, Mass.
Heming XingNovartis Institute for Biomedical Research, Cambridge, Mass.
Karl RungeGNS Healthcare, Cambridge, Mass.
Ann Chen WuChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass; Precision Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
Xiaofeng JiangProgram in Molecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Mass.
Quan LuProgram in Molecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Mass.
Bruce ChurchGNS Healthcare, Cambridge, Mass.
Iya KhalilGNS Healthcare, Cambridge, Mass.
Kelan TantisiraChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
Scott WeissChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
Brigham and Women's Hospital · USGNS Healthcare (United States) · USNovartis (Ireland) · IE

Funding

THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
Asthma Exacerbations and MicroRNA prediction: Treatment Response in an Underserved Ethnicity (AEM-TRUE)R01HL139634 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MCGEACHIE, MICHAEL JOHN · 2018 to 2022
$4.3M
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMAR01HL092197 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2009 to 2013
$3.6M
MICRORNAS IN CIRCULATION: ONTOLOGIES OF ASTHMA SEVERITY AND TREATMENT (MICROCOAST)R01HL127332 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2018
$3.4M
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)R01HD085993 · NICHD · HARVARD PILGRIM HEALTH CARE, INC. · PI WU, ANN CHEN · 2016 to 2020
$3.1M
Mechanism and Function of Beta-2 Adrenergic Receptor Degradation in the LungR01HL114769 · NHLBI · HARVARD SCHOOL OF PUBLIC HEALTH · PI LU, QUAN · 2013 to 2016
$1.6M
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)R01HL129935 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2017
$1.4M
NHLBI NIH HHS R01 HL092197NHLBI NIH HHS R01 HL114769NHLBI NIH HHS R01 HL127332NHLBI NIH HHS R01 HL129935NHLBI NIH HHS R01 HL139634NHLBI NIH HHS U01 HL065899NICHD NIH HHS R01 HD085993
6 · The paper itself

Abstract

backgroundVariation in response to the most commonly used class of asthma controller medication, inhaled corticosteroids, presents a serious challenge in asthma management, particularly for steroid-resistant patients with little or no response to treatment.

objectiveWe applied a systems biology approach to primary clinical and genomic data to identify and validate genes that modulate steroid response in asthmatic children.

methodsWe selected 104 inhaled corticosteroid-treated asthmatic non-Hispanic white children and determined a steroid responsiveness endophenotype (SRE) using observations of 6 clinical measures over 4 years. We modeled each subject's cellular steroid response using data from a previously published study of immortalized lymphoblastoid cell lines under dexamethasone (DEX) and sham treatment. We integrated SRE with immortalized lymphoblastoid cell line DEX responses and genotypes to build a genome-scale network using the Reverse Engineering, Forward Simulation modeling framework, identifying 7 genes modulating SRE.

resultsThree of these genes were functionally validated by using a stable nuclear factor κ-light-chain-enhancer of activated B cells luciferase reporter in A549 human lung epithelial cells, IL-1β cytokine stimulation, and DEX treatment. By using small interfering RNA transfection, knockdown of family with sequence similarity 129 member A (FAM129A) produced a reduction in steroid treatment response (P < .001).

conclusionWith this systems-based approach, we have shown that FAM129A is associated with variation in clinical asthma steroid responsiveness and that FAM129A modulates steroid responsiveness in lung epithelial cells.

Indexed as

Adrenal Cortex HormonesAnti-Asthmatic AgentsApoptosis Regulatory ProteinsAsthmaBiomarkers, TumorBudesonideCell LineChildChild, PreschoolDexamethasoneEpithelial CellsFemaleHumansMaleNedocromilNeoplasm ProteinsAdrenal Cortex HormonesAnti-Asthmatic AgentsApoptosis Regulatory ProteinsBiomarkers, TumorBudesonideDexamethasoneNedocromilNeoplasm ProteinsNIBAN1 protein, humanFAM129AgenomicsInhaled corticosteroidsReverse Engineering, Forward Simulation modelingsteroid response endophenotypesystems biology

Identifiers

PMID29410046
PMCPMC6111005
OpenAlexW2786268498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.